What is Carmat?
Founded in 2008, Carmat operates at the intersection of medical expertise and high-precision engineering. The company specializes in the manufacturing of innovative artificial heart devices designed to provide a viable treatment pathway for patients suffering from severe, chronic, or acute heart failure. By leveraging cutting-edge materials and biomechanical design, Carmat aims to mitigate the mortality rates associated with cardiovascular disease. Since its public listing in 2019, the firm has scaled its operations across Europe, North America, and Asia, establishing itself as a critical player in the global MedTech landscape. Its commitment to research and development remains the cornerstone of its market position, as it continues to navigate the complex regulatory and clinical environments inherent in life-critical medical device manufacturing.
How much funding has Carmat raised?
Carmat has raised a total of $25.9M across 2 funding rounds:
Other Financing Round
$18.6M
Other Financing Round
$7.4M
Other Financing Round (2022): $18.6M with participation from EIC Accelerator
Other Financing Round (2023): $7.4M led by Sante Technology Holdings
Key Investors in Carmat
Sante Technology Holdings
A diversified holding company with interests in industrial materials and strategic technology investments, providing capital support for high-growth medical innovation.
EIC Accelerator
A European innovation funding body that supports high-impact startups and SMEs with the potential to create new markets or disrupt existing ones.
What's next for Carmat?
The recent influx of capital is expected to catalyze Carmat's strategic roadmap, focusing on the optimization of its manufacturing processes and the expansion of its clinical footprint. As the company transitions into a more mature phase of enterprise-level growth, the focus will likely shift toward increasing production capacity to meet the rising demand for advanced cardiac support systems. Furthermore, the strategic backing from key institutional partners provides the necessary liquidity to sustain long-term research initiatives and potential market penetration in new territories. Investors are closely monitoring the company's ability to scale its technology while maintaining the rigorous safety and efficacy standards required for implantable medical devices, a critical factor for sustained long-term valuation.
See full Carmat company page
